Review Course Learning Objectives

Friday, February 19, 2021

Management of Behçet’s Disease – Haner Direskeneli

In this session the spectrum of different manifestations, the diagnostic approach with new tools and the therapeutic aspects of BD management will be discussed.  

At the end of this session, participants will be able to:

  1. understand the assessment of different manifestations of Behcet’s disease
  2. understand the use of imaging and biomakers for diagnosis and assessment of disease activity
  3. review current therapeutic approaches in BD management

CanMEDS roles 

  1. Medical Expert
  2. Scholar
  3. Professional
SpondyloarthritisDirk Elewaut

The gut plays an important role in spondyloarthritides, the classical example being IBD-Associated Arthritis. However, also in patients lacking gastrointestinal symptoms, the gut appears to play an important role. Hence, about half of these patients display microscopic gut inflammation and this is accompanied by profound changes in the mucosal immune system. In line with this, several studies pinpoint the presence of a profound intestinal dysbiosis which seems to be linked to disease activity. Given that some current therapeutics appear to have opposing efficacy on gut and joint symptoms whereas others seem to operate equivalent in different manifestations of the disease, understanding immunobiology of mucosal inflammation is key for our understanding of spondyloarthritis.

At the end of this session, participants will be able to:

  1. understand the value of gut inflammation in SpA
  2. integrate gut and joint disease phenotyping in therapy decision
  3. correlate gut immunobiology with therapy responses

CanMEDS roles 

  1. Medical Expert
  2. Leader
  3. Professional
Update in Rheumatoid Arthritis TreatmentLouis Bessette

This session will review new scientific data on therapeutic strategies and new therapeutic options, as well as discuss the data on dose reduction and treatment discontinuation strategies.

At the end of this session, participants will be able to:

  1. review recent data on treatment strategies and new therapeutic options in the management of RA
  2. evaluate the effectiveness of different strategies aimed at reducing or withdrawing treatment
  3. describe the strengths and weaknesses of the currently published data

CanMEDS roles 

  1. Medical Expert
  2. Communicator
  3. Health Advocate
  4. Scholar
Therapeutic strategies for Juvenile Idiopathic ArthritisJoost Swart

The current status of Step-up, Step-down, Treat-to-target and biomarker guided therapies in JIA will be discussed. The impact of definitions for outcome measures (e.g. inactive disease, VAS well-being or physician global assessment) will be shown. The risk of side effects and comorbidities (e.g. uveitis) in JIA should guide therapy as well.

At the end of this session, participants will be able to:

  1. evaluate the current status of Step-up, Step-down, Treat-to-target and biomarker guided therapies
  2. understand the impact of definitions for outcome measures (e.g. inactive disease, VAS well-being or physician global assessment)
  3. describe the (risk of) comorbidities (e.g. uveitis) in JIA

CanMEDS roles 

  1. Medical Expert
  2. Communicator
Update on Systemic Lupus ErythematosusStephanie Keeling

This session will review the best practices in diagnosing, assessing and managing lupus using a “phenotype” approach. Treatment strategies for different presentations of lupus will be discussed. New and upcoming treatments for lupus will also be introduced.

At the end of this session, participants will be able to:

  1. understand current best practices in assessing and managing lupus patients
  2. discuss treatment strategies for different phenotypes of lupus
  3. review new and upcoming treatments for lupus

CanMEDS roles 

  1. Medical Expert
  2. Leader
  3. Scholar
Autoinflammatory Disease:  More than a FeverDilan Dissanayake

The session will provide a review of the genotypes, phenotypes and targeted management approaches for a variety of autoinflammatory diseases.

At the end of this session, participants will be able to:

  1. differentiate common autoinflammatory diseases based on clinical presentation
  2. describe genetic and molecular contributors to autoinflammatory diseases
  3. apply an understanding of the pathology of autoinflammatory diseases to targeted management approaches

CanMEDS roles 

  1. Medical Expert
  2. Collaborator
  3. Scholar
GIOP: Gee…. I Ordered Prednisone – Heather McDonald-Blumer

Rheumatologists are uniquely positioned to create and ameliorate GIOP risk in our patients.  This session will cover the relevant literature and provide clinicians with a practical approach to investigation, prevention and treatment of GIOP.

At the end of this session, participants will be able to:

  1. review relevant guidelines 
  2. discuss nuances of pharmacologic Rx 
  3. integrate best practices into clinical scenarios

CanMEDS roles 

  1. Medical Expert
  2. Communicator
  3. Health Advocate
  4. Scholar